anti-CD22 ADC TRPH-222

{
  "id": "MLC-T-ONC-010306",
  "term": "anti-CD22 ADC TRPH-222",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of an anti-CD22 humanized monoclonal antibody site-specifically conjugated, via formylglycine (FG) residues and a protease insensitive 4AP linker, to a cytotoxic microtubule-targeting maytansinoid payload, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of TRPH-222 binds to B-cell-specific CD22 receptors and is rapidly internalized, thereby delivering the payload intracellularly. Upon proteolytic cleavage, the maytansinoid payload binds to tubulin, disrupting microtubule assembly/disassembly dynamics, inhibiting both cell division and tumor cell proliferation. CD22, a cell surface sialoglycoprotein, is expressed on mature B-cells and on most malignant B-cells. The site specific and stable conjugation to the payload allows for a higher drug-to-antibody ratio (DAR) and an enhanced therapeutic index.",
  "synonyms": [
    "anti-CD22 antibody-drug conjugate TRPH-222",
    "anti-CD22-4AP ADC TRPH-222"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-cd22-adc-trph-222/"
}